SYMPRO-Lung: weekly symptom monitoring, five months of median survival

Design

post-hoc survival analysis of a multicentre, stepped-wedge, cluster-randomised trial across 14 Dutch centres, Cox mixed-effects modelling

Population

446 of 515 enrolled patients with stage I–IV lung cancer starting new treatment; 235 intervention, 211 control; median follow-up 50 months

Primary outcome

overall survival (the trial's own primary outcome was health-related quality of life)

Effect

median overall survival 26 vs 21 months; adjusted hazard ratio 0.80 (95% CI 0.63–1.00), p=0.049; progression-free survival 0.86 (0.70–1.07), p=0.18

Patient-reported outcome monitoring has been shown to extend survival before, but in resource-intensive trials confined to advanced cancer, which made it easy to dismiss as unaffordable and narrow. SYMPRO-Lung tested it in routine care: a stepped-wedge cluster-randomised trial across 14 Dutch centres, where every hospital began with standard care and crossed over at predefined times to an intervention of weekly online symptom assessments for one year. Patients had stage I–IV lung cancer and were starting new treatment.

This post-hoc analysis covers 446 of the 515 enrolled patients, at a median follow-up of 50 months. Median overall survival was 26 months with monitoring and 21 months without. Adjusted for age, sex, stage, histology, performance status, treatment line and site clustering, the hazard ratio for overall survival was 0.80 (95% CI 0.63–1.00, p=0.049). Progression-free survival did not differ significantly (0.86, 0.70–1.07, p=0.18).

Read the caveats plainly: this is a post-hoc analysis of a trial whose primary endpoint was quality of life, the confidence interval touches 1.00, and 13% of patients were excluded from the analysis. But the intervention is a weekly questionnaire with a response pathway, the effect is consistent with earlier trials in advanced disease, and the mechanism is not mysterious — symptoms reported early get acted on early. Progression-free survival being flat while overall survival moves is exactly what that mechanism predicts, since better management of toxicity and complications extends life without changing tumour biology.

• The intervention is the response pathway, not the questionnaire — an alert nobody acts on within a day does nothing.
• This covered stage I–IV, so it is not confined to the palliative setting where the earlier evidence sat.
• Weekly online assessment presumes digital access and literacy; in Indian practice a structured telephone call from a nurse is the transferable version.
• Flat progression-free survival with improved overall survival points at earlier management of toxicity and complications, which is where to invest.
• Costs are staff time for triaging responses; that is the line item that determines whether this is implemented.

Why it matters

It brings a survival argument to a supportive-care intervention that services routinely defer for lack of one.

Don't overread it

A post-hoc survival analysis of a quality-of-life trial, with a confidence interval touching 1.00 — this supports implementation, it does not prove a survival benefit.

The statistics, in plain English

A hazard ratio of 0.80 with an upper bound of exactly 1.00 and p=0.049 is a result at the boundary — it would not survive much scrutiny as a primary endpoint, and it is not one. This was a post-hoc survival analysis of a trial powered for quality of life, so the p value has no protection from multiplicity and should be read as a consistent signal rather than a definitive result. The stepped-wedge design also means intervention and control periods differ in calendar time, and lung cancer treatment changed substantially between 2019 and 2021 — the adjustment includes treatment line but cannot fully handle that.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.